To PFKFB3 or Not to PFKFB3, That Is the Question

Cristina Branco; Randall S Johnson

doi:10.1016/j.ccell.2016.11.007

To PFKFB3 or Not to PFKFB3, That Is the Question

Cancer Cell. 2016 Dec 12;30(6):831. doi: 10.1016/j.ccell.2016.11.007.

Authors

Cristina Branco¹, Randall S Johnson²

Affiliations

¹ Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK.
² Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK; Department of Cell and Molecular Biology, The Karolinska Institute, Stockholm S-171 77, Sweden. Electronic address: rsj33@cam.ac.uk.

PMID: 27960081
DOI: 10.1016/j.ccell.2016.11.007

Abstract

In this issue of Cancer Cell, Cantelmo et al. describe how reduction of PFKFB3 enzyme activity can promote vascular normalization. The authors show in turn how this affects vascular permeability and can ultimately improve the efficacy of chemotherapeutic agents.

MeSH terms

Antineoplastic Agents*
Humans
Phosphofructokinase-2*

Substances

Antineoplastic Agents
Phosphofructokinase-2